Background: According to epidemiological data, over 450 million people worldwide suffer from mental disorders, presenting one of the major challenges of modern medicine. In their everyday lives, patients, in addition to fighting the disease itself, often struggle with stigmatization. This phenomenon negatively affects both the diagnostic and therapeutic processes, as well as the patients' everyday functioning. This study aimed to assess stigma attitudes toward psychiatry and psychiatric patients among undergraduate medical students.Methods: This study used a Computer-Assisted Web Interview (CAWI), which included the standardized items from the Mental Illness: Clinicians' Attitudes (MICA-2) scale to evaluate stigma. The study was disseminated via the internet to students from medical universities from 65 countries worldwide. Participation was voluntary and anonymous. The study involved 1,216 students from these 65 countries. Most of the sample were women, and most were medical faculty students and students living in cities with more than 500,000 residents. Taking into consideration Gross Domestic Product (GDP) per capita and Human Development Index (HDI) variables, it can be seen that there was a prevalence of medical students from highly developed countries.Results: For the whole sample, the mean MICA-2 score was 40.5 points. Women and medical and nursing students showed more positive attitudes toward psychiatric patients. Students from countries with the highest economic development levels also achieved statistically lower MICA-2 scores. Lower score means a more positive attitude.Conclusion: Stigma toward both psychiatry and psychiatric patients is common among undergraduate medical students. Female students and respondents with a history of mental disorders in countries with high HDI and GDP per capita indices show more favorable attitudes than other medical students. There is a need to further our understanding of the problem of stigmatization, both among the general population and among medical personnel, and to implement and maintain appropriate measures to reduce stigma toward psychiatry.

Background: More than a year after the first case of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) viral pneumonia, the world is still engulfed by the pandemic, and we know that this condition has an enormous impact not only on individuals but also on the social order in virtually every aspect of daily life, deteriorating our mental health. This study aims to assess the prevalence of depressive and anxiety symptoms and the subjective assessment of the quality of life in the different stages of the COVID-19 (Coronavirus Disease 2019) pandemic based on a nationwide online survey.Materials and Methods: The study was conducted using an original questionnaire assessing the sociodemographic status and standardized psychometric tools: Beck Depression Inventory (BDI), Generalized Anxiety Disorder (GAD-7) and Manchester Short Assessment of Quality of Life (MANSA). The study was conducted in two stages corresponding to the first and second wave of the COVID-19 pandemic.Results: In total, 4,083 respondents participated in the survey. The first observation stage took place between 17 and 26 April 2020 and comprised 2,457 respondents; the repeated survey that took place between 1 and 30 December 2020 comprised 1,626 respondents. In both cases, women constituted the majority of respondents (82.5% in the first stage and 79.6% in the second stage). Statistically significantly higher levels of depression and anxiety were found in second stage, with mean scores of BDI and GAD-7. In the case of MANSA, participants in the different stages of the pandemic showed no significant differences in terms of mean scores. However, women were more susceptible to developing the depression and anxiety symptoms and it was obtained in both waves of the pandemicConclusions: As the Covid-19 pandemic progressed, there was higher level of depressive and anxiety symptoms among Poles.

The COVID-19 pandemic has a significant impact on human life. This study aims to assess the prevalence of depressive and anxiety symptoms, and the assessment of the quality of life in different stages of the COVID-19 pandemic based on an online nationwide survey. The study was based on a voluntary, anonymous, and authors' own questionnaire. The first section assesses sociodemographic status. Then, standardized psychometric tools were used such as the Beck Depression Inventory (BDI), the Generalized Anxiety Disorder Assessment (GAD-7), and the Manchester Short Assessment of Quality of Life (MANSA). The study was conducted in three stages corresponding to the waves of the COVID-19 pandemic in Poland. The survey involved 5,790 respondents; 2,457, 1,626, and 1,707 for the first, second, and third pandemic wave, respectively. It was found that anxiety and depressive symptoms increased as the pandemic progressed. There was no significant effect on the subjective quality-of-life assessment. Moreover, there was a gradual decrease in anxiety about being infected with COVID-19 as well as reduced adherence to the Minister of Health's recommendations. As the COVID-19 pandemic progressed, depressive and anxiety symptoms increased among Poles. Women, singles, and people with prior psychiatric treatment are more likely to develop the aforementioned symptoms.

Introduction: The COVID-19 pandemic has affected the mental health of the population. This study aims to assess the prevalence of subjective depressive and anxiety symptoms as well as assess the quality of life in different waves of the COVID-19 pandemic based on an online survey. Methods: The study was conducted based on an original and anonymous questionnaire, consisting of a section assessing sociodemographic status and psychometric tools: Beck Depression Inventory (BDI), Generalised Anxiety Disorder Assessment (GAD-7) and Manchester Short Assessment of Quality of Life (MANSA). A total of 6739 people participated in the survey, with the largest number from the first wave of the pandemic (2467—36.6%), followed by 1627 (24.1%) for the second wave, 1696 (25.2%) for wave three and 949 (14.1%) for wave four. The mean age of the study group was 28.19 ± 9.94. Results: There was an initial, gradual increase in depressive and anxiety symptoms over the three waves. There were no significant differences in the quality-of-life scores, except for the second and third waves (−0.0846; p = 0.013. It was found that women, residents of big cities and people with psychiatric history showed higher BDI and GAD-7 scores. Conclusions: The impact of the pandemic on mental health was not homogeneous, with the first three waves of the COVID-19 pandemic having more of an impact compared to the fourth wave. Female respondents’ sex, history of mental disease and reduced earning capacity exacerbated psychiatric symptoms.

Accumulating evidence indicates that individuals with schizophrenia show poor dietary habits that might account for increased susceptibility to cardiovascular diseases in this population. However, it remains unknown whether this observation can be generalized over the whole population of individuals with schizophrenia. Therefore, in this study we aimed to investigate dietary habits, in terms of adherence to the Mediterranean diet (MD) in subjects with the deficit subtype of schizophrenia (SCZ-D), those with non-deficit subtype (SCZ-ND), and healthy controls (HCs). We recruited 45 individuals with SCZ-ND, 40 individuals with SCZ-D, and 60 HCs. Dietary habits were assessed using the Food Frequency Questionnaire-6 with a 12-month recall. Adherence to MD was decreased only in subjects with SCZ-D compared with HCs. Lower adherence to MD was associated with significantly higher levels of clinician-rated and self-reported negative symptoms (including alogia, avolition, and anhedonia). No significant correlations of adherence to MD with depressive symptoms were found. Lower adherence to MD was related to significantly higher body mass index in subjects with schizophrenia, but not in HCs. Our results indicate that poor adherence to MD is associated with a diagnosis of SCZ-D, higher severity of negative symptoms, and greater risk of developing overweight or obesity.